NRX Pharmaceuticals Inc. (NRXP) Revenue-to-Profit Sankey Flow & SEC XBRL Financials

Per the Roarable RQD rating, NRXP scores 36 out of 100, earning a D- grade and the verdict "Roarable Sell — Vulnerable Balance Sheet & Flow." The fundamental cash engine pillar scores 6 out of 20, reflecting an ROIC of -35% and an FCF yield of -12.25%, which indicates the business is currently consuming cash rather than generating it. The whale 13F flow pillar scores 9 out of 20 on institutional accumulation and options positioning, a moderate reading that does not offset the weak fundamentals. The insider conviction pillar scores 3 out of 20 on SEC Form 4 and Congressional PTR cluster flow, the lowest pillar and a signal of limited insider confidence per this rating. The macro regime fit pillar scores 10 out of 20, with a beta of 1.0 and sector sensitivity noted. The forensic balance sheet pillar scores 8 out of 20, drawing on an Altman Z-Score of 2.5, a Piotroski F-Score of 2/9, and a Debt/Equity ratio of 0.5. For a prospective investor, the implication is that upside depends on a turnaround in cash generation that the reported figures do not yet show; the valuation case rests on future execution rather than current earnings, and the rating frames the risk as balance sheet and flow vulnerability.

Per the SEC financials, the company reported net losses in each period shown, with operating margin and net margin both at -60% in the market data. Gross margin is 58.8%. ROIC stands at -35% and the FCF yield at -12.25%. The Altman Z-Score is 2.5 and the Piotroski F-Score is 2/9, both per the Roarable RQD rating. Debt/Equity is 0.5, and reported cash rose to $7.8M in FY 2025 from $1.4M in FY 2024, though debt figures are N/A in the filings provided.

Per <recent_news_and_catalysts>, six items are tied to NRXP. A GREEN-flagged TradingView report headlined "NRx Pharmaceuticals (NRXP) Stock Jumps Over 26% After Hours: What's Behind the Surge?" is the sole item tagged CATALYST, though its underlying drivers are not described in the source summary. A Stock Titan item reports that tests found preservative-free ketamine stayed pure, potent and sterile for two years, a product-stability data point. A Globe and Mail item notes the company has set a 2026 virtual annual meeting date. Remaining items are market-wire coverage from Yahoo! Finance Canada, Benzinga, and The Globe and Mail, flagged YELLOW. Risk watch items include the continued operating losses and cash consumption noted above. The Butterfly Supply-Chain Graph lists no supply-chain links and no proprietary signals.

• What specific products and revenue sources generate the $1.2M in FY 2025 revenue, and what drove the cash increase to $7.8M?
• What is the company's debt position, since debt figures are N/A across all reported periods?
• What catalyst drove the 26% after-hours move referenced in the TradingView headline?
• What is the runway implied by FY 2025 FCF of $-14.1M against $7.8M cash on hand?
• What institutional and insider holdings underlie the whale and insider pillar scores?